Cerebrolysin vs FGL
A side-by-side research comparison of Cerebrolysin and FGL across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | FGL |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | FGL (NCAM-Derived Peptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research compound |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | Mimics NCAM FG loop interacting with FGFR1 to promote LTP, neurite outgrowth, neuronal survival, and presynaptic function enhancement. |
| Molecular weight | <10,000 Da (peptide fraction) | ~1,800 Da |
| Half-life | 4-6 hours | 4-8 hours |
| Bioavailability | High (IM/IV) | Moderate (SubQ, partial BBB crossing) |
| Typical dose | 5-30 mL | 1-5 mg/kg (research) |
| Frequency | Daily for 10-20 days | Daily or every other day |
| Route | Intramuscular or IV | Subcutaneous |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
FGL reported benefits
- Synaptic plasticity
- LTP facilitation
- Memory improvement
- Neurotrophic effects
- FGFR activation
Related comparisons
Research and educational reference only. Not medical advice.